Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial

The Lancet Oncology
Patricia PautierFrench Sarcoma Group

Abstract

Metastatic leiomyosarcomas of uterine or soft-tissue origin have poor prognosis and moderate chemosensitivity. Trabectedin has shown activity in pretreated leiomyosarcoma. We did a single-group, multicentre, phase 2 trial (LMS-02) to assess the effect of first-line doxorubicin and trabectedin combination on disease control and survival. Adults (18 years to physiological age ≤70 years) with measurable metastatic or unresectable uterine leiomyosarcoma or soft-tissue leiomyosarcoma who had not received any previous chemotherapy were enrolled at 19 centres in France. Treatment consisted of 60 mg/m(2) intravenous doxorubicin followed by 1·1 mg/m(2) trabectedin in a 3 h intravenous infusion on day 1, both by the central venous route, and 6 mg subcutaneous pegfilgrastim on day 2, repeated every 3 weeks for up to six cycles. Surgery for residual disease was permitted. The primary endpoint was the proportion of patients achieving disease control, defined as complete or partial response or stable disease. Stratification was done by anatomical site and analyses were per protocol. This study is registered with ClinicalTrials.gov, number NCT02131480. Between July 28, 2010, and May 10, 2013, 109 patients were enrolled and treated, of whom 10...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martee L HensleyDavid R Spriggs
Jun 5, 2003·Cancer Chemotherapy and Pharmacology·Daniela MecoRiccardo Riccardi
Aug 28, 2003·Cancer·Keith M Skubitz, Amy P N Skubitz
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A YovineJ L Misset
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Garcia-CarboneroG D Demetri
Sep 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolas PenelJean-Yves Blay
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Yves BlayAxel Le Cesne
Dec 31, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C SessaL Gianni
Oct 15, 2010·Cancer·Antoine ItalianoBinh Bui
Dec 25, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N PenelP Hohenberger
Mar 13, 2014·The Lancet Oncology·Ian JudsonUNKNOWN European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

❮ Previous
Next ❯

Citations

Nov 26, 2015·Expert Opinion on Investigational Drugs·Maurizio D'Incalci, Alberto Zambelli
Jan 20, 2016·Bulletin du cancer·Nicolas MagnéStéphane Vignot
Mar 22, 2015·The Lancet Oncology·Jonathan NoujaimRobin L Jones
Apr 5, 2016·Expert Review of Anticancer Therapy·Maristella SaponaraAlessandro Gronchi
Jun 22, 2016·Expert Opinion on Pharmacotherapy·Rita De SanctisArmando Santoro
Sep 4, 2016·Taiwanese Journal of Obstetrics & Gynecology·Kuo-Chang WenUNKNOWN Taiwan Association of Gynecology Systematic Review Group
Sep 13, 2016·Expert Opinion on Pharmacotherapy·Ritika Zijoo, Margaret von Mehren
Oct 11, 2016·Sarcoma·Heather MillerMatthew L Anderson
Jan 21, 2017·Expert Review of Anticancer Therapy·Akash TiwariSameer Bakhshi
May 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Javier Martin-BrotoAndrés Poveda
Apr 21, 2017·Expert Review of Anticancer Therapy·E SkafidaA Digklia
Jan 28, 2017·BJOG : an International Journal of Obstetrics and Gynaecology·R R CuiJ Y Hou
Feb 10, 2017·Anti-cancer Drugs·Ketty TavellaTeresita Mazzei
Jul 6, 2017·Expert Opinion on Drug Metabolism & Toxicology·Simone FerreroDomenica Lorusso
Dec 19, 2017·Frontiers in Oncology·Yevette McGovernRobin L Jones
Dec 5, 2018·Expert Opinion on Investigational Drugs·Juan Martin-LiberalXavier García Del Muro
Jan 25, 2019·Current Treatment Options in Oncology·Megan Meyer, Mahesh Seetharam
Feb 7, 2019·Expert Opinion on Pharmacotherapy·Matteo TantariSimone Ferrero
Dec 9, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne GeorgeIsabelle Ray-Coquard
Aug 25, 2018·The Oncologist·Rebecca C ArendThomas J Herzog
Oct 13, 2016·Oncotarget·Amanda R DancsokTorsten O Nielsen
Mar 9, 2019·Molecular and Clinical Oncology·Théophraste HenryMichele Lamuraglia
Nov 13, 2015·Expert Review of Anticancer Therapy·Jennifer A Ducie, Mario M Leitao
Sep 25, 2015·International Journal of Surgical Pathology·Jonathan NoujaimRobin L Jones
May 24, 2017·Current Treatment Options in Oncology·Ravin Ratan, Shreyaskumar R Patel
Apr 1, 2021·Medicine·Anastasios KyriazoglouMaria Gavriatopoulou
Jul 24, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Georgios KantidakisHans Gelderblom
Aug 10, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Fan TangXia-Wei Wei
Sep 16, 2021·Current Treatment Options in Oncology·Jan Philipp Novotny, Suzanne George
Mar 9, 2018·Case Reports in Oncology·Viktoria-Anna NteliSamer El-Safadi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.